HRT Raises Risk of Lobular Breast Cancer
Incidence increased with popularity of hormone therapy, study finds.
By Amanda Gardner
E-mail this article
Subscribe to news
Printer friendly version
(SOURCES: Christopher I. Li, M.D., Ph.D., associate member, epidemiology program, Fred Hutchinson Cancer Research Center, Seattle; Jay Brooks, M.D., chairman, hematology/oncology, Ochsner Clinic Foundation, Baton Rouge, La.; Steven Goldstein, M.D., professor, obstetrics and gynecology, New York University School of Medicine, and author, The Estrogen Alternative and Could It Be Perimenopause?; January 2008 Cancer Epidemiology, Biomarkers & Prevention)
WEDNESDAY, Jan. 16 (HealthDay News) -- Not only does hormone replacement therapy raise the risk of breast cancer in postmenopausal women, it really raises the risk of a specific type of malignancy: lobular breast cancer.
The authors of a new study, which is published in the January issue of Cancer Epidemiology, Biomarkers & Prevention, also found that the cancer risk appeared earlier than the five-year period cited by other research.
The study is one of the largest to focus on lobular cancer, which accounts for about 15 percent of all cancers. Ductal cancer is the most common form of breast cancer, accounting for 70 percent of all cases, according to the study.
"We found that women who were using combined estrogen and progestin hormone therapy had a nearly 300 percent increased risk in their risk of lobular, but only a 40 percent increase in their risk of ductal cancer," said study author Dr. Christopher I. Li, an associate member in the epidemiology program at Fred Hutchinson Cancer Research Center in Seattle. "There is clear, strong, consistent evidence that using combined estrogen and progestin hormone therapy increases a woman's risk of breast cancer. It is less well known how these hormones influence risk of different types of breast cancer."
"This is basically another confirmation of previous information," added Dr. Jay Brooks, chairman of hematology/oncology at Ochsner Health System in Baton Rouge, La. "People who take combined estrogen and progestin are running a significant risk of cancer and heart disease. They really need to know that."
Others, however, downplayed the results.
"I'm a bit underwhelmed with this article," said Dr. Steven Goldstein, a professor of obstetrics and gynecology at New York University School of Medicine and author of The Estrogen Alternative and Could It Be Perimenopause?. "Nothing in this paper is new as far as I'm concerned. It doesn't change the current recommendations which are that we should use hormone therapy in 1) the lowest effective dose; 2) for the shortest period of time possible; and 3) consistent with patient treatment goals with reevaluation periodically."
Previous studies, namely the Women's Health Initiative (WHI), found that combined estrogen and progestin hormone replacement therapy increased the risk of breast cancer. Further studies have indicated that the risk is greater with lobular carcinoma than with ductal carcinoma, but these studies have not been definitive.
Lobular cancer develops in the areas of the breast that contain milk-producing glands and is more likely to be estrogen-receptor positive and therefore responsive to targeted treatments, resulting in an 11 percent lower risk of death when compared with its ductal counterpart.
Ductal cancer develops in the ducts that carry milk from the lobules to the nipple and is more difficult to detect.
The rates of both invasive lobular carcinoma (ILC) and invasive ductal-lobular cancer (IDLC) increased 52 percent and 96 percent, respectively, from 1987 to 1999 in the United States. Invasive ductal carcinoma (IDC) increased only 3 percent during the same period, according to the study.
Since the WHI results were announced in 2003 and 2004, HRT use has declined 38 percent to 68 percent in the United States. Nevertheless, some 57 million prescriptions for postmenopausal HRT are still filled each year, according to the study.
Li and colleagues looked at more than 1,500 postmenopausal women, 1,044 with breast cancer and 469 controls. Among the women with breast cancer, 324 had lobular cancer, 196 had mixed ductal-lobular cancer, and 524 had ductal cancer. The women were 55 to 74 years of age and had been diagnosed between 2000 and 2004.
Women currently using combined hormone therapy had a 2.7-fold increased risk of lobular cancer and a 3.3-fold increased risk of mixed ductal-lobular cancer. The increased risk was seen only in women who had used combined HRT for three or more years.
In women who had mixed cancers, HRT increased the risk of tumors that were primarily lobular but not those that were primarily ductal in nature. Current use of combined HRT was associated with about double the risk of tumors that were mostly lobular (although this was not considered statistically significant), about a fivefold increased risk of mostly ductal, and a 7.7-fold increased risk in tumors that were mixed in features.
Like the WHI, this study did not show an increased risk of breast cancer in women who were taking estrogen-only hormone therapy (only recommended for women who have had a hysterectomy).
The National Breast Cancer Foundation Inc. has more on different types of breast cancer.
Copyright © 2008 ScoutNews, LLC. All rights reserved.
HealthDayNews articles are derived from various sources and do not reflect federal policy. healthfinder.gov does not endorse opinions, products, or services that may appear in news stories. For more information on health topics in the news, visit the healthfinder.gov health library.